Off-market insider buying at Cardiol Therapeutics (T:CRDL)

David Elsley, a Senior Officer and Director, acquired 240,000 Common Shares (Class A) on a direct ownership basis at a price of $2.390 through a prospectus or prospectus exempt offering on June 4th, 2020. The insider also acquired 120,000 Warrants with an exercise price of $3.250 for 24 months. This represents a $573,600 investment into the company's shares and an account share holdings change of 8.8%.

In addition, Peter Pekos, a Director, acquired 40,000 Common Shares (Class A) and 20,000 Warrants on an indirect ownership basis. This represents a $95,600 investment into the company's shares and an account share holdings change of 9.9%. Colin George Stott, a Director, also acquired 40,000 Common Shares (Class A) and 20,000 Warrants on a direct ownership basis. This represents a $95,600 investment into the company's shares and an account share holdings change of greater than 100%.

Cardiol Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.